Edwards Lifesciences Corporation
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Director or officer changeAug 28 →InsidersNo open-market buys. 8 insiders sold $23.1M, 27 of 41 sales on a 10b5-1 plan.→HoldersBlackRock 10.2%Vanguard 6.5%Vanguard Portfolio 4.6%→PeersClosest companies: BSX, MMSI, MDT→
From the filings
Figures
- Revenue
- $6.51Blast 12 months
- Net income
- $1.00Blast 12 months
- Operating cash flow
- $1.36Blast 12 months
- Cash and equivalents
- $2.91Bat the last balance sheet
- Total debt
- $598.7Mat the last balance sheet
- Shares outstanding
- 576.6M shareson issue